COMMUNIQUÉS West-GlobeNewswire

-
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025 -
Cartesian Therapeutics Announces New Employment Inducement Grant
03/10/2025 -
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
03/10/2025 -
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025 -
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
03/10/2025 -
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025 -
Nomination de Marc Le Bozec comme Directeur Général par interim
03/10/2025 -
Angelini Ventures Leads €12 Million Follow-On Investment in Serenis, a Fast-Growing Digital Mental and Physical Health Company
03/10/2025 -
Change in the Roche Board of Directors
03/10/2025 -
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
03/10/2025 -
FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer
03/10/2025 -
Appointment of Marc Le Bozec as Interim CEO
03/10/2025 -
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
03/10/2025 -
Corvus Pharmaceuticals Appoints David Moore to Board of Directors
02/10/2025 -
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
02/10/2025 -
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
02/10/2025 -
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/10/2025 -
Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option
02/10/2025 -
Dyne Therapeutics Appoints Brian Posner to its Board of Directors
02/10/2025
Pages